This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

NCT ID: NCT07303790

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-20
• Study Completion Date: 2028-12-10

Brief Summary

This is an early exploratory study to assess the tolerability and safety of GC012F CAR T cell injection in Multiple Sclerosis patients.

Detailed Description

This is a single-arm, open-label, early exploratory clinical study to evaluate the safety and efficacy of GC012F Injection in patients with MS, as well as to assess its PK and PD profiles.

This study consists of the following periods: screening period, apheresis day, baseline period, lymphodepletion preconditioning period, GC012F infusion, safety and efficacy follow-up period, and long-term follow-up period.

In this study, a single dose group is planned for the CAR-T cell infusion dose,and 15 evaluable subjects will be included. Eligible subjects will receive a single infusion of GC012F Injection and will be monitored for DLTs within 28 days following the infusion of GC012F Injection.

After all the 6 subjects have completed DLT observation, all clinical study safety data collected during the DLT observation phase will be assessed. 9 subjects will be enrolled in the dose expansion phase.

After CAR-T cell infusion, subjects will be followed up for safety, cell proliferation and survival, and efficacy until 672 days (96 weeks) after infusion, withdrawal from the study, death, withdrawal of informed consent, or lost to follow-up, whichever occurs first.

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis; CAR-T cell therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GC012F CAR-T Cell Injection

This study is an early exploratory. The main purpose is an IIT clinical trial to evaluate the safety and efficacy of GC012F dual CAR-T injection in Multiple Sclerosis patinents . The enrolled patients were patients with Multiple Sclerosis .

Group Type: EXPERIMENTAL

GC012F CAR-T Cell Injection

Intervention Type: DRUG

A single dose group is planned for the CAR-T cell infusion dose is administrated for each subject.Single IV infusion.

Interventions

GC012F CAR-T Cell Injection

A single dose group is planned for the CAR-T cell infusion dose is administrated for each subject.Single IV infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. The laboratory test results at screening must meet the following criteria:

• a)Absolute neutrophil count ≥ 1.0 × 10^9/L (no growth factor is given for supportive care within 7 days prior to testing);
• b)Absolute lymphocyte count ≥ 1.0×10^9/L;
• c)Hemoglobin ≥ 80 g/L (no red blood cell transfusion is given within 7 days prior to testing);
• d)Platelet count ≥ 50×10^9/L (no blood transfusion is given within 7 days prior to testing);
• e)Serum IgG ≥ 500 mg/dL;
• f)Activated partial thromboplastin time ≤ 1.5 × upper limit of normal (ULN), prothrombin time (PT) ≤ 1.5 × ULN;
• g)Adequate renal, hepatic, cardiopulmonary function : i.Serum alanine aminotransferase and aspartate aminotransferase ≤ 3 × ULN; ii.Total bilirubin < 2 × ULN (direct bilirubin ≤ 1.5 × ULN for subjects with Gilbert's syndrome); iii.Creatinine ≤ 2 mg/dL or creatinine clearance ≥ 60 mL/min (estimated according to the Cockcroft Gault formula); iv.Subjects with left ventricular ejection fraction ≥ 45% (performed within 8 weeks prior to apheresis) as diagnosed by echocardiography (ECHO) or multi-gated acquisition scan and no evidence of pericardial effusion as determined by ECHO and no clinically significant electrocardiographic findings; v.Baseline oxygen saturation > 92% under indoor air conditions; vi.Estimated glomerular filtration rate ≥ 60 mL/min/1.73 m^2.
• 2.Confirmed diagnosis of MS based on the 2017 McDonald diagnostic criteria and diagnosis of relapsing or progressive MS based on the 2013 Lublin phenotype criteria for multiple sclerosis;

• Relapsing-remitting multiple sclerosis (RRMS):

1. patients with RRMS who have failed ≥ 1 highly effective disease modifying therapy (DMT) (fingolimod, siponimod, ozanimod, and anti-leukocyte cluster of differentiation [CD] 20 monoclonal antibody therapy, etc.) (defined as at least 12 months of continuous use).

2. At least 2 clinical relapses in the past 2 years, or 1 clinical relapse in the past 2 years with ≥ 1 new Gd-enhancing lesion on MRI, or ≥ 1 new Gd-enhancing lesion on MRI within the past 6 months; c) ≥ 2 Gd-enhancing lesions on T1-weighted brain MRI at screening.

• Primary progressive multiple sclerosis (PPMS):

1. patients with primary progressive MS who have failed highly effective DMT and whose disease activity has worsened recently (i.e., within 1 year) (EDSS disease progression score ≥ 0.5);

2. no Gd-enhancing lesions on brain MRI at screening.

• Secondary progressive multiple sclerosis (SPMS):

1. patients with secondary progressive MS who have failed highly effective DMT and whose disease activity has worsened recently (i.e., within 1 year) (EDSS disease progression score ≥ 0.5);

2. no Gd-enhancing lesions on brain MRI at screening.

• 3.EDSS score ≥ 2.0 and ≤ 6.5;
• 4.Documented history or confirmation at screening of the presence of oligoclonal bands or an elevated IgG index in CSF.

• 32.Subjects who are unwilling or unable to undergo MRI per protocol requirements, such as those who are unable to undergo MRI due to claustrophobia, or those with clear contraindications to MRI (e.g., metal implants, metal foreign bodies in the body, cardiac pacemakers, defibrillators, etc.);
• 33.Initiation of any DMT (except for protocol-permitted bridging therapies, such as low-dose hormones) between completion of apheresis and initiation of lymphodepletion;
• 34.Circumstances that, as judged by the investigator, may hinder the subject's full participation in the study or confuse the study results, or render participation in this study not in the subject's best interests."

Exclusion Criteria

• 1.Fungal, bacterial, viral, or other infection not controlled and/or requiring hospitalization or intravenous antimicrobial therapy within 4 weeks prior to screening. Uncomplicated urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to current therapy;
• 2.Active tuberculosis or latent tuberculosis that has not been treated appropriately prior to screening;
• 3.History of severe hypersensitivity or allergy;
• 4.Primary immunodeficiency;
• 5.Impaired cardiac function or clinically significant cardiac disease;
• 6.History of serious respiratory diseases or current serious respiratory diseases, including moderate or severe or above asthma or chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis;
• 7.Current or history of cirrhosis;
• 8.History of Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus within the past 2 years, and the need for continuous use of systemic immunosuppressants/systemic disease-modifying drugs;
• 9.Any active malignancy or history of malignancy within 5 years prior to screening. The following are exceptions: early-stage tumors that have undergone radical treatment (carcinoma in situ or stage I tumors, non-ulcerative primary melanoma with a depth < 1 mm and no lymph node involvement), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid carcinoma in situ or early-stage thyroid cancer that has undergone radical treatment, cervical carcinoma in situ, or breast cancer in situ that has undergone potentially radical treatment;
• 10.Those who have clinically significant bleeding symptoms or definite haemorrhagic diathesis within 6 months prior to screening;
• 11.Arterial or venous thrombotic events such as cerebrovascular disorders (including cerebral hemorrhage, cerebral infarction, etc), deep venous thrombosis, and/or pulmonary embolism within 6 months prior to screening;
• 12.Hematologic disorders: History of cytopenia consistent with myelodysplastic syndrome; history of sickle-cell anemia or other hemoglobinopathies;
• 13.Severe underlying medical conditions, such as:

1. Significant clinical evidence of dementia or mental status changes;

2. History of any other central nervous system (CNS) disorders or neurodegenerative diseases, such as epilepsy, seizure, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, and psychosis;

3. Mental disorders or psychosocial conditions that place patients at unacceptable risk.

• 14.Positive results in any of the following tests:

1. Positive for human immunodeficiency virus (HIV) antibody;

2. Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb) with hepatitis B virus deoxyribonucleic acid (DNA) above the lower limit of detection of the assay;

3. Positive for hepatitis C virus (HCV) antibody with HCV ribonucleic acid (RNA) above the lower limit of detection of the assay;

4. Positive for antibodies against human T-cell lymphotropic virus types I and II;

5. Positive for syphilis antibody. As the immunosuppression included in this study may pose an unacceptable risk, those with active HIV infection, hepatitis B (positive for HBsAg), or HCV infection (positive for anti-HCV antibodies) are excluded. Subjects are allowed to have a previous history of hepatitis B or C, provided that viral load is shown to be below the limit of detection by quantitative polymerase chain reaction and/or nucleic acid testing. Hepatitis B surface antibodies produced following hepatitis B vaccination are not considered evidence of prior infection.

• 15.Administration of a live attenuated vaccine within 4 weeks prior to apheresis;
• 16.Receipt of a different investigational drug in a clinical trial within 4 weeks prior to apheresis, or the time interval from the last dose of the investigational drug in the previous drug clinical trial to the informed consent form (ICF) signing date is still within 5 half-lives of that drug (whichever is longer);
• 17.Splenectomy within 12 months prior to the signing of ICF;
• 18.Prior therapy targeting CD19 and/or BCMA, or CAR T product therapy against any target;
• 19.Receipt of rituximab within 6 months or ofatumumab within 4 months prior to apheresis;
• 20.Patients treated with siponimod and ozanimod within 1 month prior to apheresis;
• 21.Patients treated with fingolimod within 6 weeks prior to apheresis;
• 22.Patients treated with teriflunomide within 3 months prior to apheresis;
• 23.Major surgery within 8 weeks before the signing of ICF or planned surgery during the study (except for subjects scheduled for surgery under local anesthesia, provided that the surgery will not be performed within 2 weeks after infusion);
• 24.Previous history of organ transplantation;
• 25.Confirmed diagnosis of monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, and progressive isolated sclerosis based on the 2017 McDonald criteria;
• 26.History of neuromyelitis optica spectrum disorder or myelin oligodendrocyte glycoprotein antibody-related disease, or neurological diseases suspected of MS at screening;
• 27.History of CNS or spinal cord tumors, metabolic or infectious spinal cord lesions, hereditary progressive CNS diseases, sarcoidosis, or non-MS progressive neurological diseases that interfere with study assessments;
• 28.CNS disorders, such as cerebrovascular ischemia/hemorrhage, dementia, previous or current spinal cord lesions, cerebellar diseases unrelated to MS, or other diseases deemed by the investigator to potentially interfere with neurotoxicity assessment;
• 29.History of seizures, even if seizures have been well controlled with antiepileptic drugs;
• 30.MS lesions or symptoms that have the potential to increase the risk of neurotoxicity, including but not limited to tumor-like lesions (≥ 3 cm in diameter within 5 years prior to screening) or depressed level of consciousness, and/or the presence of active, clinically significant concomitant CNS pathological changes other than MS, which may impact interpretation of study results or complicate identification or assessment of neurotoxicity;
• 31. Any contraindications to lumbar puncture (LP), including but not limited to:

1. Known or suspected structural abnormalities of the lumbar vertebra that, in the opinion of the investigator, may interfere with the conduct of LP or increase the risk of the procedure to the subject;

2. Risk of increased or uncontrollable bleeding, including but not limited to vascular abnormalities or tumors at or around the LP site, coagulation cascade disorders, abnormal platelet function, or abnormal platelet counts;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daishi Tian

OTHER

Sponsor Role: lead

Responsible Party

Daishi Tian

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Daishi Tian, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tongji Hospital

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology

Hubei, Hubei, China

Countries

China

Central Contacts

Daishi Tian, Ph.D.

Role: CONTACT

Phone: +8613607178809

Email: tiands@tjh.tjmu.edu.cn

Other Identifiers

D831DN00001

Identifier Type: -

Identifier Source: org_study_id